Macimorelin

Macimorelin
Names
IUPAC name
2-Amino-N-[(2R)-1-[[(1R)-1-formamido-2-(1H-indol-3-yl)ethyl]amino]-3-1H-indol-3-yl)-1-oxopropan-2-yl]-2-methylpropanamide
Other names
Aib-Trp-gTrp-CHO; AEZS-130; JMV 1843; Macimorelin acetate
Identifiers
381231-18-1
945212-59-9 (acetate)
ChemSpider 7980698
Jmol interactive 3D Image
PubChem 9804938
Properties
C26H30N6O3
Molar mass 474.57 g·mol−1
Pharmacology
ATC code V04CD06
Except where otherwise noted, data are given for materials in their standard state (at 25 Â°C [77 Â°F], 100 kPa).
Infobox references

Macimorelin (INN) is a drug being developed by Æterna Zentaris for use in the diagnosis of adult growth hormone deficiency. As of January 2014, it is in Phase III clinical trials.[1]

Macimorelin is a mimic of ghrelin, a growth hormone secretagogue. It binds to the growth hormone secretagogue receptor (GHSR) causing release of growth hormone from the pituitary gland.[2][3][4]

See also

References

  1. ↑ "Aeterna Zentaris NDA for Macimorelin Acetate in AGHD Accepted for Filing by the FDA". Wall Street Journal. January 6, 2014.
  2. ↑ "Macimorelin". NCI Drug Dictionary. National Cancer Institute.
  3. ↑ Koch, Linda (2013). "Growth hormone in health and disease: Novel ghrelin mimetic is safe and effective as a GH stimulation test". Nature Reviews Endocrinology 9 (6): 315. doi:10.1038/nrendo.2013.89.
  4. ↑ Garcia, J. M.; Swerdloff, R.; Wang, C.; Kyle, M.; Kipnes, M.; Biller, B. M. K.; Cook, D.; Yuen, K. C. J.; Bonert, V.; Dobs, A.; Molitch, M. E.; Merriam, G. R. (2013). "Macimorelin (AEZS-130)-Stimulated Growth Hormone (GH) Test: Validation of a Novel Oral Stimulation Test for the Diagnosis of Adult GH Deficiency". Journal of Clinical Endocrinology & Metabolism 98 (6): 2422. doi:10.1210/jc.2013-1157.



This article is issued from Wikipedia - version of the Monday, January 25, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.